A naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative and preparation method thereof

CN116102562BActive Publication Date: 2024-11-26XUZHOU NORMAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310129281.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-02-17
Publication Date
2024-11-26
Estimated Expiration
2043-02-17

AI Technical Summary

Technical Problem

[0005]该方法仅适用于合成取代形式简单的环辛内酯类化合物,难以将吲哚等具有重要药理活性的杂环或芳环拼接到环辛内酯骨架中

Benefits of technology

[0025] The process flow of the present invention is simple. Through a one-step efficient conversion process, the efficient construction of the naphtho[2,1-b]indolo[2,3-d] cyclooctolactone skeleton can be achieved, and the synthesis efficiency and step economy can be achieved High; the preparation method is simple to operate, has mild reaction conditions, and does not require the use of metal catalysts and inert gases. Protection can be carried out smoothly under air and room temperature conditions; the functional groups such as fluorine, bromine, and ester groups in the target product can undergo further transformation and functionalization reactions to facilitate diversified structural modifications of the target product. The advantages of this preparation process The target product has good anti-tumor activity and can be used in anti-tumor drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116102562B_ABST
    Figure CN116102562B_ABST
Patent Text Reader

Abstract

The invention discloses a naphtho[2,1-b]indole[2,3-d]cyclooctanolide derivative and a preparation method thereof. The chemical structural formula of the derivative is shown in Formula 1. The preparation method comprises the following steps: adding a compound of Formula 2 and a compound of Formula 3 as reaction raw materials into an organic solvent, stirring and reacting for 72-75 hours at 20-25°C under the catalysis of scandium trifluoromethanesulfonate, 4-dimethylaminopyridine and a compound of Formula 4, and in the presence of an oxidant compound of Formula 5 and a dehydrating agent #imgabs0# molecular sieve, tracking the reaction until it is complete by TLC, filtering, concentrating and separating by column chromatography to obtain a naphtho[2,1-b]indole[2,3-d]cyclooctanolide derivative of a compound of Formula 1. The derivative has good sensitivity and cytotoxic activity to human renal cancer cell Ketr-3; the method has a simple process flow, mild reaction conditions and can achieve one-step efficient conversion. #imgabs1#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of organic compound synthesis, and in particular to a naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative and a preparation method thereof. Background Art

[0002] Medium-ring lactones are an important class of organic compounds with a broad spectrum of physiological and pharmacological activities. For example, Octalactin A has anti-melanoma and colon tumor activity in mice. Indole compounds are an important class of nitrogen-containing organic heterocyclic compounds with important biological activities (Contemporary Chemical Industry, 2022, 51(3), 718-722). The synthesis of octalactone compounds containing indole fragments using the active group splicing method is of great significance for the development and research of new drugs.

[0003] A method for preparing a cyclooctanolactone derivative has been reported in the literature: under the action of boron trifluoride etherate and 2,4,6-trimethylpyridine, 2-methoxytetrahydropyran and substituted silyloxyalkyne undergo cyclization reaction to generate a cyclooctanolactone derivative, and the reaction formula is as follows:

[0004]

[0005] This method is only applicable to the synthesis of cyclooctanolactone compounds with simple substitution forms, and it is difficult to splice heterocyclic or aromatic rings with important pharmacological activities such as indole into the cyclooctanolactone skeleton.

[0006] Therefore, developing a simple and efficient active group splicing method to synthesize cyclooctanolactone compounds containing heterocyclic or aromatic ring fragments such as indole is of great significance for the development and research of new drugs. Summary of the invention

[0007] The purpose of the present invention is to provide a naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative and a preparation method thereof. The derivative has good sensitivity and cytotoxic activity to human renal cancer cell Ketr-3. The method has a simple process flow, mild reaction conditions and can achieve one-step efficient conversion.

[0008] To achieve the above object, the present invention provides a naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative, the chemical structure of which is shown in Formula 1:

[0009]

[0010] In formula 1, R 1 is selected from the group consisting of hydrogen, halogen, halogen-substituted C1-C2 alkyl, and methyl ester; R 2 is selected from hydrogen or halogen.

[0011] The present invention also provides a method for preparing the naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative, comprising the following steps:

[0012] The 1-(1H-indol-2-yl)naphthalene-2-ol derivative of the compound of formula 2 and the 3-benzinylaldehyde derivative of the compound of formula 3 are added as reaction raw materials into an organic solvent, and under the catalysis of scandium trifluoromethanesulfonate, 4-dimethylaminopyridine, the compound of formula 4 (5aS, 10bR)-2-phenyl-2,5a,6,10b-tetrahydro-4H-indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinyl-11-ium tetrafluoroborate, and the oxidant compound of formula 5 3,3',5,5'-tetra-tert-butyl-[1,1'-di(cyclohexadiene)]-2,2',5,5'-tetraene-4,4'-dione and a dehydrating agent, a reaction mixture is prepared. In the presence of molecular sieves, stirring the reaction at 20-25° C. for 72-75 hours, tracking the reaction by TLC until completion, filtering, concentrating, and separating by column chromatography to obtain a naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative of Formula 1;

[0013] The molar ratio of the compound of formula 2, 1-(1H-indol-2-yl)naphthalene-2-ol derivative, the compound of formula 3, 3-benzylaldehyde derivative, 4-dimethylaminopyridine, scandium trifluoromethanesulfonate, the compound of formula 4, (5aS,10bR)-2-phenyl-2,5a,6,10b-tetrahydro-4H-indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinyl-11-ium tetrafluoroborate and the compound of formula 5, 3,3',5,5'-tetra-tert-butyl-[1,1'-di(cyclohexadiene)]-2,2',5,5'-tetraene-4,4'-dione is 1.0:3.5:1:0.2:0.15:3;

[0014] The structural formula of the 1-(1H-indol-2-yl)naphthalene-2-ol derivative of the compound of formula 2 is

[0015] In formula 2, R 1 One selected from hydrogen, halogen, halogen-substituted C1-C2 alkyl, and methyl ester;

[0016] The structural formula of the 3-benzinyl aldehyde derivative of the compound of formula 3 is In formula 3, R 2 is selected from hydrogen or halogen;

[0017] The compound of formula 4 (5aS, 10bR)-2-phenyl-2,5a,6,10b-tetrahydro-4H-indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinyl-11-ium tetrafluoroborate has a structural formula of

[0018] The structural formula of the compound of formula 5, 3,3',5,5'-tetra-tert-butyl-[1,1'-di(cyclohexadiene)]-2,2',5,5'-tetraene-4,4'-dione, is

[0019] Preferably, the 1-(1H-indol-2-yl)naphthalene-2-ol derivative of the compound of formula 2 is selected from 1-(5-(trifluoromethyl)-1H-indol-2-yl)naphthalene-2-ol, 1-(5-fluoro-1H-indol-2-yl)naphthalene-2-ol, 1-(5-bromo-1H-indol-2-yl)naphthalene-2-ol, 1-(1H-indol-2-yl)naphthalene-2-ol, and 1-(5-(methyl formate)-1H-indol-2-yl)naphthalene-2-ol.

[0020] Preferably, the 3-benzinyl aldehyde derivative of the compound of formula 3 is selected from 3-benzinyl aldehyde and 3-(3-bromophenyl)propyne aldehyde.

[0021] Preferably, the organic solvent is tetrahydrofuran.

[0022] Preferably, The amount of molecular sieve used is 0.5-1.5 g / mmol of the compound of formula 2.

[0023] Preferably, the amount of organic solvent used is 20-30 ml / mmol of the compound of formula 2.

[0024] Compared with the prior art, the present invention has the following beneficial effects:

[0025] The process flow of the invention is simple and efficient, and the efficient construction of the naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone skeleton can be achieved through a one-step efficient conversion process, and the synthesis efficiency and step economy are high; the preparation method is easy to operate, and the reaction conditions are mild, and no metal catalyst and inert gas protection are required, and the method can be smoothly carried out under air and room temperature conditions; the fluorine, bromine, ester group and other functional groups in the target product can undergo further conversion and functionalization reactions, which facilitates diversified structural modification of the target product; the target product of the preparation process has good anti-tumor activity and can be applied to anti-tumor drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 This is the hydrogen nuclear magnetic resonance spectrum of the target compound I synthesized in Example 1 of the present invention;

[0027] Figure 2 This is the hydrogen nuclear magnetic resonance spectrum of the target compound II synthesized in Example 2 of the present invention;

[0028] Figure 3 This is the hydrogen nuclear magnetic resonance spectrum of the target compound III synthesized in Example 3 of the present invention;

[0029] Figure 4 This is the hydrogen nuclear magnetic resonance spectrum of the target compound IV synthesized in Example 4 of the present invention;

[0030] Figure 5 This is the hydrogen nuclear magnetic resonance spectrum of the target compound V synthesized in Example 5 of the present invention;

[0031] Figure 6 This is a schematic diagram comparing the cytotoxic inhibition rate of the target compound I synthesized in Example 1 of the present invention on Ketr-3;

[0032] Figure 7 This is a schematic diagram comparing the cytotoxic inhibition rate of the target compound II synthesized in Example 2 of the present invention on Ketr-3;

[0033] Figure 8 This is a schematic diagram comparing the cytotoxic inhibition rate of the target compound III synthesized in Example 3 of the present invention on Ketr-3;

[0034] Fig. 9 This is a schematic diagram comparing the cytotoxic inhibition rate of the target compound IV synthesized in Example 4 of the present invention on Ketr-3;

[0035] Fig.10 This is a schematic diagram comparing the cytotoxic inhibition rate of the target compound V synthesized in Example 5 of the present invention on Ketr-3. DETAILED DESCRIPTION

[0036] The present invention is further described in detail below with reference to specific embodiments.

[0037] In the following examples, unless otherwise specified, the experimental methods are usually carried out under conventional conditions or conditions recommended by the manufacturer; the raw materials and reagents can be obtained by commercial purchase.

[0038] Example 1

[0039] A method for preparing a naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative I, comprising the following specific steps:

[0040] 1-(5-fluoro-1H-indol-2-yl)naphthalene-2-ol (0.3 mmol), 3,3',5,5'-tetra-tert-butyl-[1,1'-di(cyclohexadiene)]-2,2',5,5'-tetraene-4,4'-dione (0.9 mmol), 4-dimethylaminopyridine (0.3 mmol,), Molecular sieves (300 mg), scandium trifluoromethanesulfonate (0.06 mmol), (5aS,10bR)-2-phenyl-2,5a,6,10b-tetrahydro-4H-indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazin-11-ium tetrafluoroborate (0.045 mmol), tetrahydrofuran (7.5 mL) and 3-phenylindole aldehyde (1.05 mmol) were reacted at 20°C for 3 days. After the reaction, the solvent was removed and column chromatography was used to separate and obtain a pure naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative I: 3-phenyl-naphtho[2,1-b]-5-fluoro-indolo[2,3-d]-cyclooctanolactone, the reaction formula is as follows:

[0041]

[0042] Yield: 51%; yellow solid;

[0043] like Figure 1 As shown, the hydrogen nuclear magnetic resonance spectrum of the target compound I (CDCl3, 400 MHz) (δ, ppm): 9.06 (s, 1H), 7.92–7.86 (m, 1H), 7.56–7.50 (m, 1H), 7.39–7.26 (m, 4H), 7.26–7.21 (m, 3H), 6.99–6.90 (m, 1H), 6.52 (d, J=9.2 Hz, 1H), 6.42 (s, 1H).

[0044] Example 2

[0045] A method for preparing a naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative II, comprising the following specific steps:

[0046] 1-(5-bromo-1H-indol-2-yl)naphthalene-2-ol (0.3 mmol), 3,3',5,5'-tetra-tert-butyl-[1,1'-di(cyclohexadiene)]-2,2',5,5'-tetraene-4,4'-dione (0.9 mmol), 4-dimethylaminopyridine (0.3 mmol), Molecular sieves (300 mg), scandium trifluoromethanesulfonate (0.06 mmol), (5aS,10bR)-2-phenyl-2,5a,6,10b-tetrahydro-4H-indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazin-11-ium tetrafluoroborate (0.045 mmol), tetrahydrofuran (7.5 mL) and 3-phenylindole aldehyde (1.05 mmol) were reacted at 20°C for 3 days. After the reaction, the solvent was removed and column chromatography was used to separate and obtain a pure naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative II: 3-phenyl-5-bromonaphtho[2,1-b]indolo[2,3-d]cyclooctanolactone, the reaction formula of which is as follows:

[0047]

[0048] Yield: 48%; yellow solid;

[0049] like Figure 2 As shown, the hydrogen nuclear magnetic resonance spectrum of the target compound II (CDCl3, 400 MHz) (δ, ppm): 8.97 (s, 1H), 7.90 (d, J = 8.4 Hz, 2H), 7.84 (d, J = 8.8 Hz, 1H), 7.56–7.51 (m, 2H), 7.33–7.27 (m, 5H), 7.26–7.20 (m, 3H), 7.02 (s, 1H), 6.44 (s, 1H).

[0050] Example 3

[0051] A method for preparing a naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative III, comprising the following specific steps:

[0052] 1-(5-(trifluoromethyl)-1H-indol-2-yl)naphthalene-2-ol (0.3 mmol), 3,3',5,5'-tetra-tert-butyl-[1,1'-di(cyclohexadiene)]-2,2',5,5'-tetraene-4,4'-dione (0.9 mmol), 4-dimethylaminopyridine (0.3 mmol,), Molecular sieves (300 mg), scandium trifluoromethanesulfonate (0.06 mmol), (5aS,10bR)-2-phenyl-2,5a,6,10b-tetrahydro-4H-indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazin-11-ium tetrafluoroborate (0.045 mmol), tetrahydrofuran (7.5 mL) and 3-benzinylaldehyde (1.05 mmol) were reacted at 20°C for 3 days. After the reaction, the solvent was removed and column chromatography was used to separate and obtain a pure naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative III: 3-phenyl-5-trifluoromethylnaphtho[2,1-b]indolo[2,3-d]cyclooctanolactone. The reaction formula is as follows:

[0053]

[0054] Yield: 74%; yellow solid;

[0055] like Figure 3 As shown, the target compound has a hydrogen nuclear magnetic resonance spectrum (CDCl3, 400 MHz) (δ, ppm): 9.29 (s, 1H), 7.93–7.88 (m, 1H), 7.86–7.82 (m, 1H), 7.57–7.53 (m, 1H), 7.50–7.36 (m, 3H), 7.35–7.27 (m, 7H), 7.26–7.22 (m, 1H), 7.17 (s, 1H), 6.48 (s, 1H).

[0056] Example 4

[0057] A method for preparing a naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative IV, comprising the following specific steps:

[0058] 1-(5-(Methylformyl)-1H-indol-2-yl)naphthalen-2-ol (0.3 mmol), 3,3',5,5'-tetra-tert-butyl-[1,1'-di(cyclohexadiene)]-2,2',5,5'-tetraene-4,4'-dione (0.9 mmol), 4-dimethylaminopyridine (0.3 mmol,), Molecular sieves (300 mg), scandium trifluoromethanesulfonate (0.06 mmol), (5aS, 10bR)-2-phenyl-2,5a,6,10b-tetrahydro-4H-indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazin-11-ium tetrafluoroborate (0.045 mmol), tetrahydrofuran (7.5 mL) and 3-phenylindole aldehyde (1.05 mmol) were reacted at 20°C for 3 days. After the reaction, the solvent was removed and column chromatography was used to separate and obtain a pure naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative IV: 3-phenyl-5-methylcarbonate naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone, the reaction formula is as follows:

[0059]

[0060] Yield: 80%; yellow solid;

[0061] like Figure 4 As shown, the target compound has a hydrogen nuclear magnetic resonance spectrum (CDCl3, 400 MHz) (δ, ppm): 9.53 (s, 1H), 7.91–7.83 (m, 1H), 7.63 (s, 1H), 7.53–7.49 (m, 1H), 7.43 (d, J=8.8 Hz, 1H), 7.32–7.26 (m, 5H), 7.25–7.20 (m, 1H), 6.48 (s, 1H), 3.75 (s, 3H).

[0062] Example 5

[0063] A method for preparing a naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative V, comprising the following specific steps:

[0064] 1-(1H-indol-2-yl)naphthalene-2-ol (0.3 mmol), 3,3',5,5'-tetra-tert-butyl-[1,1'-di(cyclohexadiene)]-2,2',5,5'-tetraene-4,4'-dione (0.9 mmol), 4-dimethylaminopyridine (0.3 mmol,), Molecular sieves (300 mg), scandium trifluoromethanesulfonate (0.06 mmol), (5aS,10bR)-2-phenyl-2,5a,6,10b-tetrahydro-4H-indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazin-11-ium tetrafluoroborate (0.045 mmol), tetrahydrofuran (7.5 mL) and 3-(3-bromophenyl)propynoic aldehyde (1.05 mmol) were reacted at 20°C for 3 days. After the reaction, the solvent was removed and column chromatography was used to separate and obtain a pure naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative V: 3-(3-bromophenyl)-naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone, the reaction formula of which is as follows:

[0065]

[0066] Yield: 85%; yellow solid;

[0067] like Figure 5 As shown, the hydrogen nuclear magnetic resonance spectrum of the target compound (CDCl3, 400 MHz) (δ, ppm): 8.95 (s, 1H), 7.97–7.88 (m, 3H), 7.57–7.47 (m, 4H), 7.44 (d, J = 7.6 Hz, 1H), 7.38 (d, J = 8.8 Hz, 1H), 7.28 (s, 1H), 7.18 (d, J = 7.6 Hz, 1H), 7.13–7.07 (m, 1H), 7.06–6.99 (m, 1H), 6.93 (d, J = 8.0 Hz, 1H), 6.42 (s, 1H).

[0068] For example, the CCK8 method was used to determine the growth inhibition ability of the target compounds I-V prepared in Examples 1-5 on human renal cancer cell Ketr-3. The target compounds I-V were diluted with dimethyl sulfoxide to three concentrations of 1, 10, and 100 ng / mL, and their cytotoxicity to Ketr-3 was determined after 24 hours of action. The results are shown in Tables 1 and Figure 6-Figure 10 As shown, from the results analysis in the table and the figure, it can be seen that the above-mentioned target compound naphtho[2,1-b]indole[2,3-d]cyclooctanolide compounds have good activity in inhibiting the growth of tumor cells and can be used to inhibit the growth of tumor cells, which has important guiding significance and application prospects for the discovery of new and efficient anti-tumor drugs.

[0069] Table 1 Inhibition rate of target compounds I-V on Ketr-3 at different concentrations

[0070]

[0071]

[0072] The process flow of the present invention is simple, and through a one-step efficient conversion process, the efficient construction of the naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone skeleton can be achieved, and the synthesis efficiency and step economy are high. The preparation method is easy to operate, and the reaction conditions are mild. It does not require the use of metal catalysts and inert gas protection, and can be smoothly carried out under air and room temperature conditions. The fluorine, bromine, ester group and other functional groups in the target product can undergo further conversion and functionalization reactions, which facilitates the diversified structural modification of the target product, has good anti-tumor activity, and can be applied to anti-tumor drugs.

Claims

1. A naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative, characterized in that: Its chemical structure is shown in Formula 1: ; In formula 1, R 1 is selected from the group consisting of hydrogen, halogen, halogen-substituted C1-C2 alkyl, and methyl formate; R 2 is selected from hydrogen or halogen.

2. A method for preparing the naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative as claimed in claim 1, characterized in that: The steps include: The 1-(1H-indol-2-yl)naphthalene-2-ol derivative of the compound of formula 2 and the 3-benzinylaldehyde derivative of the compound of formula 3 are added as reaction raw materials into an organic solvent, and the reaction is carried out at 20-25 ℃ under the catalysis of scandium trifluoromethanesulfonate, 4-dimethylaminopyridine, and the compound of formula 4 (5aS,10bR)-2-phenyl-2,5a,6,10b-tetrahydro-4H-indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinyl-11-ium tetrafluoroborate, and in the presence of an oxidant compound of formula 5 3,3',5,5'-tetra-tert-butyl-[1,1'-di(cyclohexadiene)]-2,2',5,5'-tetraene-4,4'-dione and a dehydrating agent 4Å molecular sieve. The mixture was stirred at ℃ for 72-75h, and the reaction was followed by TLC until completion. The mixture was filtered, concentrated, and separated by column chromatography to obtain a naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative of Formula 1; The molar ratio of the compound of formula 2, 1-(1H-indol-2-yl)naphthalene-2-ol derivative, the compound of formula 3, 3-benzylaldehyde derivative, 4-dimethylaminopyridine, scandium trifluoromethanesulfonate, the compound of formula 4, (5aS,10bR)-2-phenyl-2,5a,6,10b-tetrahydro-4H-indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinyl-11-ium tetrafluoroborate and the compound of formula 5, 3,3',5,5'-tetra-tert-butyl-[1,1'-di(cyclohexadiene)]-2,2',5,5'-tetraene-4,4'-dione is 1.0:3.5:1:0.2:0.15:3; The structural formula of the 1-(1H-indol-2-yl)naphthalene-2-ol derivative of the compound of formula 2 is , in formula 2, R 1 One selected from hydrogen, halogen, halogen-substituted C1-C2 alkyl, and methyl formate; The structural formula of the 3-benzinyl aldehyde derivative of the compound of formula 3 is , in formula 3, R 2 is selected from hydrogen or halogen; The compound of formula 4 (5aS, 10bR)-2-phenyl-2,5a,6,10b-tetrahydro-4H-indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinyl-11-ium tetrafluoroborate has a structural formula of ; The structural formula of the compound of formula 5, 3,3',5,5'-tetra-tert-butyl-[1,1'-di(cyclohexadiene)]-2,2',5,5'-tetraene-4,4'-dione, is .

3. The method for preparing a naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative according to claim 2, characterized in that: The 1-(1H-indol-2-yl)naphthalene-2-ol derivative of the compound of formula 2 is selected from 1-(5-(trifluoromethyl)-1H-indol-2-yl)naphthalene-2-ol, 1-(5-fluoro-1H-indol-2-yl)naphthalene-2-ol, 1-(5-bromo-1H-indol-2-yl)naphthalene-2-ol, 1-(1H-indol-2-yl)naphthalene-2-ol, and 1-(5-(methyl formate)-1H-indol-2-yl)naphthalene-2-ol.

4. The method for preparing a naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative according to claim 2, characterized in that: The 3-benzinyl aldehyde derivative of the compound of formula 3 is selected from one of 3-benzinyl aldehyde and 3-(3-bromophenyl)propyne aldehyde.

5. The method for preparing a naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative according to claim 2, characterized in that: The organic solvent is tetrahydrofuran.

6. The method for preparing a naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative according to claim 2, characterized in that: The amount of 4Å molecular sieve used is 0.5-1.5 g / mmol of the compound of formula 2.

7. The method for preparing a naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative according to claim 2, characterized in that: The amount of organic solvent used is 20-30 ml / mmol of the compound of formula 2.

8. The method for preparing a naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative according to claim 2, characterized in that: The reaction was stirred at 20 °C for 72 h.

9. The method for preparing a naphtho[2,1-b]indolo[2,3-d]cyclooctanolactone derivative according to claim 2, characterized in that: The eluent used in the column chromatography is a mixture of petroleum ether and ethyl acetate in a volume ratio of 20:1.